Menu

NIH Won’t Use Industry Money for Opioid Research Initiative

The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.

Apr 19, 2018
Shawna Williams

ISTOCK, MITCHELL WESSELLSThe National Institutes of Health (NIH) will exclusively use taxpayer money for a research initiative on the treatment of pain and substance use disorder, STAT News reports. The announced funding is a shift from what had been touted as a potential public-private partnership, with the federal government and drug companies each contributing approximately $200 million to the initiative.

The change comes after an NIH working group recommended last month that only federal funds be used for planned research aimed at alleviating the opioid crisis. The intent is “[t]o mitigate the risk of real or perceived conflict of interest,” the working group noted. The shift away from using private money for the initiative also comes amid controversy over an NIH agency’s courting of industry funders for a proposed study on the health effects of drinking alcohol.

“There’s so much controversy swirling around pharmaceuticals on the opioid issue,” Rep. Tom Cole (R-Okla.), who chairs the House appropriations subcommittee on health, tells STAT, adding that he agrees with NIH’s decision. An NIH spokesperson tells the outlet that the planned research can proceed with only federal funds thanks to budget increases in last month’s omnibus spending bill.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.